Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.50 |
| ▸ | KIT | P10721 | 7/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.47 |
| ▸ | GAK | O14976 | 2/20 | 0.45 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13669265 | 0.90 | GAK (0.54) | AAK1KITNTRK1PIK3CAGAK | |
| SCHEMBL13745818 | 0.89 | KDR (0.51) | PTPN11BRD4 | |
| SCHEMBL13745605 | 0.85 | PTPN11 (0.45) | PTPN11BRD4 | |
| SCHEMBL3348977 | 0.84 | HTR6 (0.48) | BRD4 | |
| SCHEMBL15607500 | 0.84 | AAK1 (0.52) | AAK1KITNTRK1PIK3CAGAK | |
| SCHEMBL13746279 | 0.84 | MAPK8 (0.53) | PTPN11BRD4 | |
| SCHEMBL13746490 | 0.83 | BRD4 (0.43) | PTPN11BRD4 | |
| SCHEMBL4337406 | 0.82 | BRD4 (0.59) | AAK1KITNTRK1PIK3CAGAK | |
| SCHEMBL8443781 | 0.82 | BRD4 (0.44) | PTPN11BRD4 | |
| SCHEMBL13746283 | 0.82 | PTPN11 (0.43) | KITPTPN11BRD4ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014004863-A2 | COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2014-01-03 | — | — | WO | disclosed |
| WO-2014004863-A2 | COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2014-01-03 | — | — | WO | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | AAK1 182/4885KIT 3148/4885NTRK1 1855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.